Alzheimer’s
Lundbeck’s Alzheimer’s drug shows promise
May 29, 2012Research and Development, Sales and Marketing Alzheimer's, Lundbeck
Lundbeck’s Alzheimer’s candidate Lu AE58054 has shown signs in a phase II study of helping patients’ mental activity. Sufferers receiving …
Lipitor losses hit Pfizer
May 2, 2012Sales and Marketing Alzheimer's, Lipitor, Pfizer, patent expiry
Lipitor’s US patent expiry has inflicted heavy damage on Pfizer’s revenues, with global sales down 7% in the first three …
Alzheimer’s diagnostic comes with caveats
April 10, 2012Sales and Marketing Alzheimer's, Amyvid, lilly
A first-in-class test for Alzheimer’s disease has been approved by the FDA, but its makers have stressed its limitations.Lilly’s Amyvid …
UK government launches new dementia programme
March 26, 2012Medical Communications, Sales and Marketing Alzheimer's, Cameron, UK, dementia
The government has signalled its intention to boost dementia funding and awareness with its new ‘challenge on dementia’ campaign. In …
Teva launches generic Aricept in the UK
February 16, 2012Manufacturing and Production, Sales and Marketing Alzheimer's, Aricept, NHS, Pfizer, Teva
Teva has launched its generic version of Alzheimer’s drug Aricept, as the drug loses its patent protection in the UK. …
AstraZeneca to take Alzheimer’s drug into phase II
January 5, 2012Research and Development Alzheimer's, AstraZeneca, Targacept
AstraZeneca is to continue the development of Targacept’s AZD1446 as a treatment for Alzheimer’s disease.AZD1446 is a selective modulator of …
Nanoparticles to target Alzheimer’s disease
August 10, 2011Research and Development Alzheimer's, nanoparticles
Researchers at Lancaster University funded by the European Union are hoping to develop a new treatment for Alzheimer’s disease. Nanoparticles …
Tangles and plaques: unlocking the secrets of Alzheimer’s disease
March 11, 2011Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, bapineuzumab, dimebon, latrepirdine, solanezumab
Despite many years of relentless research efforts, Alzheimer’s disease, the most common form of dementia, remains impossible to cure. According …
Diabetes drugs show promise in Alzheimer’s
January 17, 2011Research and Development Alzheimer's, Alzheimer’s, Byetta, Novo Nordisk, Victoza, diabetes, exenatide, lilly, liraglutide
Research suggests that new diabetes drugs enhance cell growth in the brain, and could help treat Alzheimer’s disease. Researchers at …
Biogen Idec buys neurodegenerative disease rights
December 21, 2010Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases
Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …
Europe’s neurologists unfamiliar with emerging Alzheimer’s drugs
November 17, 2010Research and Development, Sales and Marketing Alzheimer's, Aricept, Decision Resources, Europe, Pfizer
A survey of neurologists in Europe has shown only a minority are aware of late stage drugs being developed to …
Alzheimer’s disease
October 16, 2010Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, Elan, J&J, JJ, Pfizer, lilly, pharmaceutical
In 1906 a psychiatrist working in a Frankfurt asylum became fascinated by the unnamed illness suffered by one of his …
Battle for Alzheimer’s drugs finally over
October 8, 2010Sales and Marketing Alzheimer's, Aricept, NICE
NICE is to allow wider access to Alzheimer’s disease treatments, ending an epic five year battle for access to the …
NICE announces change of heart on Alzheimer’s
October 7, 2010Sales and Marketing Alzheimer's, Aricept, Ebixa, Exelon, NICE, Reminyl
NICE is set to update its guidance on treatments for Alzheimer´s disease, widening access to four drugs. The draft guidance …
Nestlé to pioneer ‘health science nutrition’
September 29, 2010Sales and Marketing Alzheimer's, health science nutrition, nestle
Nestlé is to take on conditions such as diabetes, obesity, cardiovascular disease and Alzheimer’s with the creation of two research …
Latest content
Recruitment experts hired in search for new CGT Catapult chief
Envirogen secures place on NHS Scotland reverse osmosis framework
